RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on returning blood cancers
Disease control OngoingThis early-stage study tests a new treatment for people with certain B-cell blood cancers (like lymphomas and leukemias) that have come back. The treatment involves taking a patient's own white blood cells, adding a new gene to help them find and kill cancer cells, and giving the…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 04:25 UTC
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis early-stage study tests the safety and best dose of two drugs—ibrutinib and lenalidomide—given together to people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The goal is to find a dose that is safe and tolerable, while also seeing …
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
New drug cocktail shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis early-stage study is testing a combination of three drugs—obinutuzumab, venetoclax, and lenalidomide—in people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. The main goal is to find the safest dose and see how well the drugs work togethe…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Beth Christian • Aim: Disease control
Last updated May 17, 2026 04:12 UTC
-
New drug combo shows promise for patients with relapsed lymphoma
Disease control OngoingThis study tests whether combining two immunotherapy drugs (rituximab and pembrolizumab) with or without a chemotherapy drug (lenalidomide) can shrink tumors in people whose follicular lymphoma or diffuse large B-cell lymphoma has returned after previous treatment. About 53 adult…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Disease control OngoingThis study tests a treatment using a patient's own immune cells, modified in a lab to recognize and attack a protein called CD20 on lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. The goal is to find the safe…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Two-Drug combo shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis early-phase study tested a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and vorinostat (a drug that blocks enzymes cancer cells need to grow)—in 52 adults with certain types of lymphoma that had returned or stopped resp…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
Double-targeted cell therapy takes on hard-to-treat blood cancers
Disease control OngoingThis early-phase trial is testing a new type of immunotherapy for people with certain blood cancers (like lymphoma and leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to recogniz…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New combo therapy aims to boost immune attack on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to standard therapy. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New hope for hard-to-treat lymphoma: targeted drug combo shows promise
Disease control OngoingThis study tests a new combination of drugs (polatuzumab vedotin plus standard chemotherapy and immunotherapy) as the first treatment after lymphoma returns or doesn't respond. About 41 adults with diffuse large B-cell lymphoma will receive this therapy to see if it can shrink tu…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Supercharged immune cells take on tough lymphoma after transplant
Disease control OngoingThis early-phase trial tests a new approach for people with aggressive B-cell non-Hodgkin lymphoma that has come back after treatment. After a standard stem cell transplant, patients receive their own immune cells (T cells) that have been genetically modified in a lab to better r…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 08, 2026 12:01 UTC
-
New combo tackles tough blood cancers
Disease control OngoingThis early-phase study tests two drugs, pevonedistat and ibrutinib, together in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effects…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 04, 2026 16:32 UTC
-
Promising lymphoma combo study pulled before it even started
Disease control TerminatedThis study planned to test a combination of three drugs (rituximab, venetoclax, and bortezomib) in adults with a type of aggressive lymphoma that had come back or stopped responding to standard treatment. The goal was to see if the combination could shrink or control the cancer. …
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 04, 2026 16:31 UTC
-
New combo aims to boost CAR-T power against tough lymphoma
Disease control OngoingThis early-stage trial tests whether adding an experimental drug called NKTR-255 to standard CAR-T cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to treatment. The study involves about 27 adults and focuses on safety and…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 04, 2026 16:22 UTC
-
New combo tackles aggressive lymphoma that Won't quit
Disease control OngoingThis early-stage study tests a combination of four drugs (atezolizumab, gemcitabine, oxaliplatin, and rituximab) in about 24 people with a type of lymphoma that has come back or stopped responding to treatment. The main goals are to find the safest dose and see how well the drugs…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:17 UTC
-
New hope for tough lymphoma: drug combo shows promise in early trial
Disease control OngoingThis early-phase study tested a new combination of drugs (carfilzomib plus standard chemotherapy) in 29 adults with diffuse large B-cell lymphoma that had come back or not responded to prior treatment. The main goals were to find the safest dose of carfilzomib and see how well th…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New combo therapy offers hope for Tough-to-Treat lymphomas
Disease control OngoingThis study tests a combination of two drugs, nivolumab and lenalidomide, in people with non-Hodgkin or Hodgkin lymphoma that has returned or no longer responds to standard treatments. The goal is to find the best dose and see how well the combination works at shrinking tumors. Ab…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC